
Conference Coverage
Latest Content

Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies

How Can Trauma Affect the Menopausal Transition?

Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD

New Immune Cell Marker Offers Clues to Kidney Disease Progression

Serum Spectroscopy Reveals Prognostic Risk Factors in CLL

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Chronic spontaneous urticaria (CSU) and atopic disorders seem to share an immunological basis and may significantly benefit from type 2 inflammation–targeted therapies.

Treatment options for patients with small cell lung cancer (SCLC) who survive to a third line of therapy are insufficient, authors of a new study argue.

The AMCP Nexus 2025 conference will bring together professionals to discuss drug access and policy, as well as the future of pharmacy.

Glucagon-like peptide 1 receptor agonists improved disease activity, body weight, and cholesterol in patients with rheumatoid arthritis.

Tumor-first multigene testing boosts diagnostic accuracy, minimizes duplication, and aligns with professional society recommendations for integrated sequencing.

Artificial intelligence models may advance clinical trial design and enrollment to improve trial success and patient outcomes.

Liver Awareness Month raises awareness of liver disease causes, risks, symptoms, and prevention, highlighting individual actions and policy efforts.

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.

Elinzanetant offers a hormone-free solution for managing menopause-related hot flashes, targeting the root cause of vasomotor symptoms.

Increases in global temperatures may exacerbate cardiovascular mortality risk in older patients with heart failure.
































































